Curia IP Holdings, LLC
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Jul 2034
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 28, 2027The maintenance fee for Polymorphic mixture of Rifaximin and its use for the preparation of solid formulations (US 11,739,099) comes due Feb 28, 2027. Unpaid by Aug 30, 2027, it lapses early.
- 1 fee due May 17, 2027The maintenance fee for Rifaximin Crystalline Forms and Methods of Preparation Thereof (US 9,186,355) comes due May 17, 2027. Unpaid by Nov 17, 2027, it lapses early.
- 1 fee due Aug 11, 2027The maintenance fee for Polymorphic mixture of Rifaximin and its use for the preparation of solid formulations (US 10,556,915) comes due Aug 11, 2027. Unpaid by Feb 11, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 7 of 7
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,018,225 | Rifaximin Crystalline Forms and Methods of Preparation Thereof In force · High confidence | In force | High confidence | |
| US 9,186,355 | Rifaximin Crystalline Forms and Methods of Preparation Thereof In force · Medium confidence | In force | Medium confidence | |
| US 10,556,915 | Polymorphic mixture of Rifaximin and its use for the preparation of solid formulations In force · USPTO record | In force | USPTO record | |
| US 10,745,415 | Polymorphic mixture of Rifaximin and its use for the preparation of solid formulations In force · USPTO record | In force | USPTO record | |
| US 10,961,257 | Polymorphic mixture of rifaximin and its use for the preparation of solid formulations In force · USPTO record | In force | USPTO record | |
| US 11,739,099 | Polymorphic mixture of Rifaximin and its use for the preparation of solid formulations In force · USPTO record | In force | USPTO record | |
| US 11,384,146 | Btla-Binding Antibodies for Modulating Immune Response and Treating Disease In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 5 no status recorded